‘No Decision’ On Sandoz As Novartis Continues To Explore Options
Update To Strategic Review Likely By The End Of The Year
Novartis said it had so far made “no decision” as it continues to consider numerous options for Sandoz, from retaining the business to separation, in order to maximize value for shareholders and capitalize upon the growing autonomy of its generics business.
